ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,143,790 | -16.4% | 774,654 | -3.9% | 0.00% | 0.0% |
| Q2 2023 | $19,315,243 | +55.1% | 806,482 | +21.9% | 0.00% | +100.0% |
| Q1 2023 | $12,452,045 | -0.5% | 661,639 | -15.8% | 0.00% | 0.0% |
| Q4 2022 | $12,515,111 | +57.9% | 786,125 | +62.3% | 0.00% | 0.0% |
| Q3 2022 | $7,924,000 | +43.9% | 484,331 | +23.9% | 0.00% | 0.0% |
| Q2 2022 | $5,506,000 | -54.6% | 390,793 | -21.9% | 0.00% | 0.0% |
| Q1 2022 | $12,119,000 | +70.7% | 500,373 | +64.5% | 0.00% | 0.0% |
| Q4 2021 | $7,100,000 | +46.9% | 304,171 | +4.5% | 0.00% | – |
| Q3 2021 | $4,832,000 | -59.4% | 290,958 | -40.4% | 0.00% | -100.0% |
| Q2 2021 | $11,915,000 | -30.0% | 488,547 | -26.0% | 0.00% | -50.0% |
| Q1 2021 | $17,028,000 | -51.6% | 660,033 | +0.4% | 0.00% | -50.0% |
| Q4 2020 | $35,162,000 | +73.1% | 657,701 | +33.6% | 0.00% | +33.3% |
| Q3 2020 | $20,313,000 | -22.7% | 492,439 | -9.2% | 0.00% | -25.0% |
| Q2 2020 | $26,281,000 | +7.3% | 542,225 | -6.4% | 0.00% | 0.0% |
| Q1 2020 | $24,485,000 | +37.3% | 579,490 | +39.0% | 0.00% | +33.3% |
| Q4 2019 | $17,838,000 | -38.3% | 416,950 | -48.1% | 0.00% | -25.0% |
| Q3 2019 | $28,910,000 | +47.9% | 803,285 | +9.9% | 0.00% | +33.3% |
| Q2 2019 | $19,544,000 | +25.5% | 731,188 | +26.1% | 0.00% | +50.0% |
| Q1 2019 | $15,567,000 | +46.3% | 579,773 | -11.9% | 0.00% | 0.0% |
| Q4 2018 | $10,639,000 | -25.0% | 658,006 | -3.7% | 0.00% | 0.0% |
| Q3 2018 | $14,186,000 | +14.5% | 683,395 | -15.7% | 0.00% | 0.0% |
| Q2 2018 | $12,386,000 | -1.9% | 811,140 | +44.3% | 0.00% | 0.0% |
| Q1 2018 | $12,632,000 | +6.9% | 562,206 | +43.2% | 0.00% | 0.0% |
| Q4 2017 | $11,818,000 | -10.5% | 392,479 | +11.9% | 0.00% | 0.0% |
| Q3 2017 | $13,208,000 | +44.6% | 350,611 | +7.1% | 0.00% | 0.0% |
| Q2 2017 | $9,132,000 | -24.1% | 327,422 | -6.4% | 0.00% | 0.0% |
| Q1 2017 | $12,031,000 | +6.2% | 349,920 | -10.9% | 0.00% | 0.0% |
| Q4 2016 | $11,329,000 | -0.1% | 392,829 | +10.2% | 0.00% | 0.0% |
| Q3 2016 | $11,339,000 | +13.4% | 356,452 | +15.7% | 0.00% | 0.0% |
| Q2 2016 | $9,995,000 | +79.1% | 307,950 | +54.3% | 0.00% | +100.0% |
| Q1 2016 | $5,581,000 | -41.9% | 199,605 | -25.9% | 0.00% | -50.0% |
| Q4 2015 | $9,600,000 | +13.7% | 269,297 | +5.5% | 0.00% | 0.0% |
| Q3 2015 | $8,443,000 | +368.5% | 255,335 | +493.6% | 0.00% | +100.0% |
| Q2 2015 | $1,802,000 | -84.9% | 43,015 | -88.3% | 0.00% | -75.0% |
| Q1 2015 | $11,968,000 | +388.5% | 367,230 | +375.6% | 0.00% | – |
| Q4 2014 | $2,450,000 | -2.4% | 77,207 | -23.8% | 0.00% | – |
| Q3 2014 | $2,509,000 | -11.7% | 101,306 | -19.5% | 0.00% | – |
| Q2 2014 | $2,841,000 | +1.5% | 125,809 | +9.4% | 0.00% | – |
| Q1 2014 | $2,798,000 | -51.1% | 115,023 | -49.8% | 0.00% | -100.0% |
| Q4 2013 | $5,720,000 | +20.5% | 228,917 | +32.5% | 0.00% | -50.0% |
| Q3 2013 | $4,747,000 | +22.7% | 172,808 | -18.9% | 0.00% | +100.0% |
| Q2 2013 | $3,868,000 | – | 213,132 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |